Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Europe GmbH, received orphan-drug designation from the European Commission for HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, for the treatment of gastric cancer. This designation, which follows a positive opinion from the European Medicines Agency, highlights the company’s progress in developing HLX22, which is undergoing various clinical trials for different cancer indications. The global market for HER2-targeting monoclonal antibody products was valued at approximately $9.029 billion in 2024, indicating significant market potential for HLX22.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative monoclonal antibody products. The company is known for its work on HER2-targeting therapies, with a market focus on treating various cancers, including gastric and breast cancer.
Average Trading Volume: 1,523,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$22.88B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.